OBJECTIVE: The Mannan-binding lectin (MBL) pathway involves recognition of fungal surfaces by MBL and cleavage of C2 and C4 by MBL-associated serine protease (namely, MASP-2). Recent data show that MBL pathway deficiency might result not only from polymorphisms of the MBL2 gene but also of MASP2. The aim of the study was to assess whether polymorphisms of these genes are associated with invasive fungal infections (IFIs) following allogeneic stem cell transplantation (allo-SCT). METHODS: The promoter and the exon 1 of MBL2 and the exon 3 of MASP2 were sequenced in 106 donor-recipient pairs from HLA-identical sibling allo-SCTs performed in a single institution. RESULTS: Ten percent of the donors and 11% of the recipients carried the MBL-low (O/O, LXA/O) genotypes; 7% of the donors and 3% of the recipients were heterozygous for the MASP2 Asp105Gly variant. Factors associated with a higher probability of IFIs were donor's MBL-low genotype (38% vs 12%, p = 0.01), recipient's MASP2 variant (67% vs 14%, p = 0.01), and acute graft-versus-host disease (GVHD) grades II to IV (27% vs 11%, p = 0.04); in the multivariate analysis MBL-low genotype (relative risk [RR] 7.3, p = 0.003), MASP2 variant (RR 6.4, p = 0.002), and acute GVHD II to IV (RR 3.8, p = 0.02) retained independent prognostic value. CONCLUSION: These results show for the first time that polymorphisms responsible for not only MBL but also MASP-2 deficiency are independent predictive factors for IFI after allo-SCT.
OBJECTIVE: The Mannan-binding lectin (MBL) pathway involves recognition of fungal surfaces by MBL and cleavage of C2 and C4 by MBL-associated serine protease (namely, MASP-2). Recent data show that MBL pathway deficiency might result not only from polymorphisms of the MBL2 gene but also of MASP2. The aim of the study was to assess whether polymorphisms of these genes are associated with invasive fungal infections (IFIs) following allogeneic stem cell transplantation (allo-SCT). METHODS: The promoter and the exon 1 of MBL2 and the exon 3 of MASP2 were sequenced in 106 donor-recipient pairs from HLA-identical sibling allo-SCTs performed in a single institution. RESULTS: Ten percent of the donors and 11% of the recipients carried the MBL-low (O/O, LXA/O) genotypes; 7% of the donors and 3% of the recipients were heterozygous for the MASP2 Asp105Gly variant. Factors associated with a higher probability of IFIs were donor's MBL-low genotype (38% vs 12%, p = 0.01), recipient's MASP2 variant (67% vs 14%, p = 0.01), and acute graft-versus-host disease (GVHD) grades II to IV (27% vs 11%, p = 0.04); in the multivariate analysis MBL-low genotype (relative risk [RR] 7.3, p = 0.003), MASP2 variant (RR 6.4, p = 0.002), and acute GVHD II to IV (RR 3.8, p = 0.02) retained independent prognostic value. CONCLUSION: These results show for the first time that polymorphisms responsible for not only MBL but also MASP-2 deficiency are independent predictive factors for IFI after allo-SCT.
Authors: Alex Smithson; Ana Muñoz; Belen Suarez; Sara Maria Soto; Rafael Perello; Alex Soriano; Jose Antonio Martinez; Jordi Vila; Juan Pablo Horcajada; Jose Mensa; Francisco Lozano Journal: Clin Vaccine Immunol Date: 2007-01-03
Authors: S Heitzeneder; P Zeitlhofer; U Pötschger; E Nowak; M G Seidel; M Hölzl; A Lawitschka; E Förster-Waldl; S Matthes-Martin; D Heja; O A Haas; A Heitger Journal: Bone Marrow Transplant Date: 2015-05-11 Impact factor: 5.483
Authors: Wei Hu; Bryan A Bassig; Jun Xu; Tongzhang Zheng; Yawei Zhang; Sonja I Berndt; Theodore R Holford; H Dean Hosgood; Brian Leaderer; Meredith Yeager; Idan Menashe; Peter Boyle; Kaiyong Zou; Yong Zhu; Stephen Chanock; Qing Lan; Nathaniel Rothman Journal: Environ Mol Mutagen Date: 2012-10-11 Impact factor: 3.216
Authors: Christopher C Dvorak; Brian T Fisher; Lillian Sung; William J Steinbach; Michael Nieder; Sarah Alexander; Theoklis E Zaoutis Journal: Pediatr Blood Cancer Date: 2011-11-18 Impact factor: 3.167
Authors: O W Neth; U Bacher; P Das; T Zabelina; H Kabisch; N Kroeger; F Ayuk; M Lioznov; O Waschke; B Fehse; R Thiébaut; R M Haston; N Klein; A R Zander Journal: Bone Marrow Transplant Date: 2009-05-11 Impact factor: 5.483